Catalent Announces Collaboration with Galapagos to Further Expand Galapagos’ Decentralized CAR-T Manufacturing Network in the U.S. Read more
Be Bio Announces Closing of $92M Series C Financing and Completes Transition to a Multi-Program, Clinical Stage Company Read more
REGENXBIO and Nippon Shinyaku Form Exclusive Partnership to Develop RGX-121 and RGX-111 for MPS Diseases Read more